โ Home
โน๏ธ Info
๐งพ At a Glance ๐ Core Facts ๐๏ธ Products/Services โญ Ratings ๐งโ๐ผ Executives ๐ฌ My Comments๐ก Analytics
๐ Insights ๐ข Company Q&A (574) ๐ ๏ธ Industry Q&A (121) ๐ Competitors ๐ Price Low ๐ Price Swings โก SWOT ๐๏ธ PEST ๐ Porter's Five Forces โจ Score Positive โ ๏ธ Risk Assessment ๐งฉ Segmentation ๐ ถ Google Links๐ Ratios
๐ฐ Margins ๐ Financial Ratios ๐ฑ Growth ๐ Enterprise Value ๐ Key Metrics ๐ต Dividends๐ง Tools
โ Due Diligence๐ข Press Releases
| Date | Press release |
|---|---|
| 2026-04-01 16:05:00 | Agree Realty Announces First Quarter 2026 Earnings Release Date And Conference Call Information Royal oak, mich.--(business wire)--agree realty corporation (nyse: adc) (the โcompanyโ) today announced that it will release its first quarter 2026 operating results after the market closes on tuesday, april 21, 2026. a conference call to discuss the companyโs operating results is scheduled for wednesday, april 22, 2026, at 9:00 am et. interested parties and shareholders may access the call via teleconference or webcast: teleconference: usa toll free (800) 715-9871 ย international (646) 307-196. |
| 2026-03-24 22:40:00 | Akeso Advances \"io 2.0 + Adc 2.0\" Strategy With Phase Ii Initiation Of Novel Adcs Combined With Ivonescimab And Cadonilimab Hong kong, march 24, 2026 /prnewswire/ --ย akeso, inc. (9926.hk)ย (โakesoโ or the โcompanyโ) announced today that it has received clearance from the center for drug evaluation (cde) of chinaโs national medical products administration (nmpa) to initiate phase ii clinical trials for ak146d1, a first-in-class trop2 /nectin4 bispecific antibody-drug conjugate (adc), and ak138d1, an innovative her3-targeting adc. the studies will evaluate these two novel adc candidates in combination with the companyโs pioneering immuno-oncology (io) 2.0 bispecific antibodies, cadonilimab (pd-1/ctla-4) and ivonescimab (pd-1/vegf), as well as other proprietary high-potential anti-tumor assets, including ak117 (anti-cd47 monoclonal antibody) and ak109 (anti-vegf monoclonal antibody), across a spectrum of advanced solid tumors. |
| 2026-03-24 08:05:00 | Vivosim Releases Antibody Drug Conjugate (adc) Data Showing Power To Detect Adc Toxicity And Guide Design Of Safer Adcs Adcs are a major new market; company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity adcs are a major new market; company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity |
| 2026-03-17 16:35:00 | Zai Lab To Present New Data On Three Internally Developed Oncology Candidates At Aacr 2026, Including Zocilurtatug Pelitecan, A Dll3-targeting Antibody-drug Conjugate (adc) Shanghai & cambridge, mass.--(business wire)--zai lab limited (nasdaq: zlab; hkex: 9688) today announced three of the companyโs internally-developed investigational oncology therapies will be presented across four poster sessions at the upcoming american association for cancer research (aacr) annual meeting 2026 taking place april 17-22 in san diego, california. these next-generation candidates include: zocilurtatug pelitecan (zoci, formerly zl-1310), a dll3-targeting antibody-drug conjugate (a. |
| 2026-03-17 16:30:00 | Whitehawk Therapeutics To Highlight Its Next-generation Adc Portfolio At The American Association For Cancer Research (aacr) Annual Meeting 2026 Morristown, n.j., march 17, 2026 /prnewswire/ -- whitehawk therapeutics, inc.ย (nasdaq: whwk), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (adc)ย cancer treatments, today announced it will present three preclinical abstracts, including an oral minisymposium and two posters, highlighting its next-generation antibody-drug conjugate (adc) portfolio at theย american association for cancer research (aacr) annual meeting 2026, taking place april 17โ22, 2026, in san diego, ca. |
| 2026-03-16 07:00:00 |
|
| 2026-03-10 16:05:00 |
|
| 2026-03-10 07:30:00 |
|
| 2026-03-03 07:15:00 |
|
| 2026-03-02 16:05:00 |
|
| 2026-02-24 07:15:00 |
|
| 2026-02-23 07:15:00 |
|
| 2026-02-11 08:45:00 |
|
| 2026-02-10 16:05:00 |
|
| 2026-02-10 03:15:00 |
|
๐ฐ Browse additional press releases for Agree Realty Corp!
Sign up for free or log in๐ฅ Get our free eBook now: "The Checklist Value Investor โ A Smarter Way to Pick Stocks"